In the context of neoadjuvant chemotherapy, the expression levels of multiple immune-related genes including CXCL13 constitute positive prognostic factors for pCR (42), and it has been demonstrated to be associated with improved disease-free and overall survival after tumor resection (43). The gene discussed is CXCL13; the disease is neoplasm.